Pharmaceutical Technology7d
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
Seeking Alpha12d
Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript
The U.S. approval of Roche's TECENTRIQ HYBREZA with ENHANZE represents the availability of the first and only subcutaneous anti- PD-L1 cancer immunotherapy. Approval was granted for all of the ...
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...
Nasdaq12d
Halozyme reports Q3 non-GAAP EPS $1.27, consensus 98c
“In the quarter, the announcement of two highly anticipated partner approvals in the U.S. for Roche’s TECENTRIQ HYBREZA and OCREVUS ZUNOVO reinforces ENHANZE’s track record of 100% phase 3 ...
Finanznachrichten12d
Halozyme Therapeutics, Inc.: Halozyme Reports Third Quarter 2024 Financial And Operating Results
"In the quarter, the announcement of two highly anticipated partner approvals in the U.S. for Roche's TECENTRIQ HYBREZA and OCREVUS ZUNOVO reinforces ENHANZE's track record of 100% phase 3 study ...
Cure Today9d
Skin Cancer
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.